| Análisis de la implementación de los Informes de Posicionamiento Terapéutico en España |
| Author(s): Míriam Solozabal, Laura Planellas, Elisabet Viayna, Neus Canal |
| Affiliations(s): Health Economics & Outcomes Research. Real-World Insights. IQVIA España |
Publication(s): Revista Española de Economía de la Salud. 2019; 14(3):596-605
|
| Document Type(s): Article, |
| Countries: Spain, |
| Click here for the abstract |
C:
Y: |
Health policy, Pricing and reimbursement, Public Health,
2019 |
|
L:
A: |
Spanish
Clinical setting: hospital, Clinical setting: Primary care, Internet or Interactive voice response system, Pricing & Reimbursement, Public Health, |
|
 |
| |
| |
| WHAT INTERPRETATION OF ICERS IN ORPHAN DISEASES? A FRENCH EXAMPLE. |
| Author(s): Moutier Hélène; Bourguignon Sandrine; Maurel Frédérique; Bodaghi Charles |
| Affiliations(s): RWI IQVIA France |
Publication(s): ISPOR 2018
|
| Document Type(s): Poster, |
| Countries: France, |
C:
Y: |
Comparative Effectiveness & Health Technology Assessment, Health economics, Pricing and reimbursement, Rare Diseases,
2018 |
|
L:
A: |
English
Cost effectiveness, Pricing & Reimbursement, Willingness to pay, |
|
|
| |
| |
| Overview of German AMNOG Dossiers with Price Analysis Before and After Early Benefit Assessment |
| Author(s): Tremmel M, Batscheider A, Bocuk D, Roxlau T, Antoni B, Elena Mihaylova, Bonduelle D |
| Affiliations(s): IQVIA Commercial GmbH & Co. OHG, Munich, Germany
IQVIA RDS Bulgaria EOOD, Sofia, Bulgaria |
| Publication(s): |
| Document Type(s): Abstract, |
| Countries: |
C:
Y: |
Health economics, Health policy, Pricing and reimbursement,
2018 |
|
L:
A: |
English
Pricing & Reimbursement, Review, |
|
|
| |
| |
| The Impact of Label Extensions on the Reimbursed Price of Pharmaceutical Products Assessed According to §35A SGB V in Germany Oncological and Metabolic Diseases |
| Author(s): Schmalhofer C, Eheberg D, Tremmel M, Bocuk D, Roxlau T, Antoni B, Bonduelle D |
| Affiliations(s): IQVIA Commercial GmbH & Co. OHG, Munich, Germany |
| Publication(s): |
| Document Type(s): Abstract, |
| Countries: Germany, |
C:
Y: |
Health economics, Health policy, Metabolic Disorders , Oncology, Pricing and reimbursement,
2018 |
|
L:
A: |
English
Cost analysis, Pricing & Reimbursement, |
|
|
| |
| |
| Healthcare Resource Utilization and Costs among Psoriasis Patients Treated with Biologics, Overall and by Disease Severity |
| Author(s): Murage MJ, Anderson A, Oliveria SA, Casso D, Ojeh CK, Muram TM, Merola JF, Araujo AB |
| Affiliations(s): Murage MJ: Eli Lilly and Company; Anderson A: IQVIA; Oliveria SA: IQVIA; Casso D: IQVIA; Ojeh CK: Eli Lilly and Company; Muram TM: Eli Lilly and Company; Merola JF: Harvard Medical School; Araujo AB: Eli Lilly and Company |
Publication(s): Journal of Medical Economics
|
| Document Type(s): Article, |
| Countries: USA, |
| Click here for the abstract |
C:
Y: |
Dermatology, Patient Registries & Real-World Study Methods, Pricing and reimbursement,
2018 |
|
L:
A: |
English
Cost analysis, Database Study, Epidemiological study, Retrospective cohort analysis, Retrospective database analysis, |
|
|
| |
| |
| Valoración de la innovación, ¿es “el innovómetro†una herramienta útil y su clasificación reproducible? |
| Author(s): Otermin A, Callejo D, Gasche D, Viayna E, Rubio M, Sumalla M, Solozabal M. |
| Affiliations(s): HEOR-RWI, IQVIA |
Publication(s): XXXVIII Jornadas de Economía de la Salud, Gran Canaria 2018
|
| Document Type(s): Poster, |
| Countries: Spain, |
| Click here for the abstract |
C:
Y: |
Health policy, Pricing and reimbursement,
2018 |
|
L:
A: |
Spanish
Pricing & Reimbursement, |
|
|
| |
| |
| How a new innovation assessment tool relates to recent drug launches for Spanish National acess |
| Author(s): Míriam Solozabal, Elisabet Viayna, Marta Rubio, Mireia Sumalla, Ane Otermin, David Gasche, Laura Planellas, Daniel Callejo |
| Affiliations(s): HEOR-RWI, IQVIA Spain |
Publication(s): ISPOR Europe 2018. 10-14 November 2018 | Barcelona, Spain
|
| Document Type(s): Poster, |
| Countries: Spain, |
| Click here for the abstract |
C:
Y: |
Pricing and reimbursement,
2018 |
|
L:
A: |
English
Clinical setting: hospital, Pricing & Reimbursement, |
|
|
| |
| |
| The impact of biosimilar launch on molecule price and pharmaceutical expense: the case of the insulin glargine in Italy |
| Author(s): Tucci C1, Cioni L1, Mantuano M1, Tettamanti A1 |
| Affiliations(s): 1 QuintilesIMS, Milan, Italy |
Publication(s): ISPOR 20th Annual European Congress, 4-8 November 2017, Glasgow, Scotland
|
| Document Type(s): Poster, |
| Countries: Italy, |
C:
Y: |
Diabetes, Health policy, Pricing and reimbursement, Regulatory,
2017 |
|
L:
A: |
English
Literature Review, Pricing & Reimbursement, Public Health, |
|
|
| |
| |
| Drug commercialization before the pricing and reimbursement in Italy: the non negotiated C Class (C-nn) |
| Author(s): Mantuano M1, Cioni L1 |
| Affiliations(s): 1 QuintilesIMS, Milan, Italy |
Publication(s): ISPOR 20th Annual European Congress, 4-8 November 2017, Glasgow, Scotland
|
| Document Type(s): Poster, |
| Countries: Italy, |
C:
Y: |
Health policy, Pricing and reimbursement, Regulatory,
2017 |
|
L:
A: |
English
Literature Review, Pricing & Reimbursement, Public Health, |
|
|
| |
| |
| Análisis de coste-efectividad de empagliflozina en pacientes con diabetes mellitus tipo 2 y enfermedad cardiovascular establecida en España [Analysis of cost-effectiveness of empagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease established in Spain]. |
| Author(s): Barrull C1, Massafrets M2, Planellas L1, Perulero N1 |
| Affiliations(s): 1 RWI, QuintilesIMS, Barcelona 2 Market Access Department, Boehringer Ingelheim, Barcelona |
Publication(s): XXXVII Jornadas de Economía de la Salud2017, 6 - 8 de septiembre, Barcelona, España
|
| Document Type(s): Poster, |
| Countries: Spain, |
| Click here for the abstract |
C:
Y: |
Cardiovascular disease, Diabetes, Health economics, Pricing and reimbursement,
2017 |
|
L:
A: |
Spanish
Clinical setting: hospital, Clinical setting: Primary care, clinical setting: Secondary care, Cost effectiveness, Cost utility, Literature Review, Patient questionnaire, Randomised controlled trial, |
|
|
| |
| |
 1 of 7 
|
